Haplomic Technologies nabs EU, US patents
Haplomic Technologies has secured European and US patents covering its key IP, which involves methods for haplotyping the human genome.
Haplotyping involves identifying through DNA sequencing the elements of a haplotype - the basic blocks of genetic material inherited from parents.
Chromosomes are a paired series of contiguous haplotype and the distribution of alleles between haplotype pairs is known as the haplotypic phase.
Current sequencing technologies and advances, including the Human Genome Project, do not take into account the haplotypic phase.
This means that if an individual has two mutations on one gene, current technologies cannot accurately determine if the mutations are present on one chromosome inherited from one parent or the two genes inherited from both parents.
Haplomic Technologies is developing technologies based around haplotyping. The technologies have applications in genomics in the fields of disease risk analysis, pharmacogenomics, personalised medicine and transplantation.
The company was founded in 2003 based on IP from Dr Malcolm Simons, the co-founder of Genetic Technologies (ASX:GTG).
Simons was the first scientist to determine that non-coding DNA regions - so-called ‘junk DNA’ - still play a functional role in genetics.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
